tiprankstipranks
InflaRx reports Q3 EPS (EUR 0.30) vs. (EUR 0.13) last year
PremiumThe FlyInflaRx reports Q3 EPS (EUR 0.30) vs. (EUR 0.13) last year
15d ago
InflaRx expects cash to fund operations into 2026
Premium
The Fly
InflaRx expects cash to fund operations into 2026
15d ago
Is IFRX a Buy, Before Earnings?
Premium
Pre-Earnings
Is IFRX a Buy, Before Earnings?
25d ago
InflaRx Announces $75M Share Sales Agreement
PremiumCompany AnnouncementsInflaRx Announces $75M Share Sales Agreement
5M ago
InflaRx’s Drug Enters BARDA Phase 2 ARDS Trial
Premium
Company Announcements
InflaRx’s Drug Enters BARDA Phase 2 ARDS Trial
5M ago
Barda selects InflaRx’s GOHIBIC for clinical trial  to evaluate ARDS therapeutic
Premium
The Fly
Barda selects InflaRx’s GOHIBIC for clinical trial to evaluate ARDS therapeutic
5M ago
InflaRx reports Q1 EPS (EUR 0.17) vs. (EUR 0.25) last year
PremiumThe FlyInflaRx reports Q1 EPS (EUR 0.17) vs. (EUR 0.25) last year
7M ago
InflaRx N.V. Announces Share Capital Amendment
Premium
Company Announcements
InflaRx N.V. Announces Share Capital Amendment
7M ago
InflaRx N.V. Announces 2024 AGM Details
Premium
Company Announcements
InflaRx N.V. Announces 2024 AGM Details
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100